Lipids-risk categories in omani type 2 diabetics: Impact of the national cholesterol educational program

Sultan Qaboos University Medical Journal

Volumn 6, Issue 2, 2006, Pages 19-25

  Al Bahrani, Ali I ^a   Bayoumi, Riad ^a   Al Yahyaee, Said A ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Diabetes mellitus; Lipids; Lipoproteins; NCEP risk score; Oman

Indexed keywords

EID: 84969423221     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Asfour MG, Lambourne A, Soliman A, et al. High prevalence of diabetes mellitus and impaired glucose tolerance in the Sultanate of Oman: Results of the 1991 national survey. Diabet Med 1995; 12:1122-1125.
2. Al-Lawati A, Riyami A, Mohammed A, Jousihati P. Increasing prevalence of diabetes mellitus in Oman. Diabet Med 2002; 19:954-957
3. Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P. Prevalence of the metabolic syndrome among Omani adults. Diabetes Care 2003; 26:1781-1785
4. American Diabetic Association. Standards of Medical care for Patients with Diabetes Mellitus. Diabetes Care 2003; 26:S33-S50
5. Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497
6. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner El. Apolipoprotein B and A-1 values in 127,576 Swedish males and females, standardized according to the World Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998; 44:1641-1649
7. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PW, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study. Clin Chem 1996; 42:515-523.
8. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
9. Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999; 100:475-482.
10. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of High-Density Lipoprotein Cholesterol Interventional Trial Study Group. N Engl J Med 1999; 341:410-18.
11. Durrington P. Calculation of coronary risk in Type II diabetes. Clinical Science 2001; 101:681-682.
12. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
13. Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 2005; 28:1029-1034.
14. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, et al. Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119:676-683.
15. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 2005; 150:859-870.
16. Guthrie RM. Rising to the challenge of treating high-risk patients. Am J Manag Care 2006; 12:S318-S324.
17. Huse DM, Song X, Ozminkowski RJ, et al. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. Clin Ther 2006; 28:1425-1442.